Qingdao,Shandong, China-October 19, 2026
Introduction
For decades, cancer researchers faced a major frustration. The signaling pathways that drive tumor growth are also required for healthy tissue function. Blocking pathways like Wnt or EGFR in a cancer cell sounds simple. However, the same inhibition destroys the intestinal lining, fractures bones, or blisters skin. A new study from researchers at Genentech published in Science Advances (Kschonsak et al., 2026) offers a compelling answer. The strategy is built on a simple idea. They paired a weak inhibitor of an oncogenic receptor with a high-affinity arm that targets a tumor-enriched surface protein. Because of this, the drug activates only where it is needed.
The Core Strategy: Guided, Conditional Inhibition
The conceptual backbone of this work rests on two insights. First, pathway-associated toxicities tend to be tissue-specific. Wnt inhibitors harm the gut and bone. EGFR inhibitors damage the skin, and FGFR1 inhibitors disrupt kidney phosphate regulation. This specificity implies that the safe zone is much larger than traditional antibody design assumed. Second, single-cell RNA sequencing (scRNA-seq) provides the resolution to find which surface proteins are expressed on tumor cells. Crucially, these proteins must be missing from the specific cell types driving toxicity, which are usually stem cell populations.
The team exploited these two facts. They engineered bispecific antibodies (bsAbs) where one arm binds weakly to the therapeutic target, such as Frizzled/FZD, EGFR, or FGFR1. Affinities were deliberately attenuated above 50 nM. This makes the arm too weak to work by itself. The second arm binds with high affinity to a tumor-enriched anchor receptor, like TROP2 or CEACAM6. On tumor cells expressing the anchor, local concentration of the bsAb occurs. Avidity-driven co-engagement of both receptors restores potent inhibitory activity. On normal cells that lack the anchor, the weak inhibitory arm never gains enough traction to cause harm. The knobs-into-holes IgG1 format was used with effector-function-ablating mutations. This framework was applied across 3 oncogenic targets. Thus, the group established it as a broadly transferable platform rather than a one-off solution.
About us
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you’re working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech’s comprehensive range of research products will help you achieve accurate and reliable results.
Media ContactCompany Name: Alpha Lifetech IncorporationContact Person: Media RelationsEmail: Send EmailPhone: +1 609-736-0910Address:90 State Street, STE 700 Office 40, Albany, NY 12207 United States Country: ChinaWebsite: https://www.alpha-lifetech.com/
